Long-term drug treatment for obesity: a systematic and clinical review.
暂无分享,去创建一个
[1] L. Aronne,et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study , 2014, International Journal of Obesity.
[2] A. Culyer. New Drug Application , 2014 .
[3] Lawrence J Appel,et al. Prevalence of obesity in the United States. , 2014, JAMA.
[4] Jennette P. Moreno,et al. Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes , 2014, Current Atherosclerosis Reports.
[5] C. Hampp,et al. Use of Prescription Antiobesity Drugs in the United States , 2013, Pharmacotherapy.
[6] L. Aronne,et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study , 2013, International Journal of Obesity.
[7] W. Garvey,et al. New tools for weight-loss therapy enable a more robust medical model for obesity treatment: rationale for a complications-centric approach. , 2013, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[8] T. Wadden,et al. Managing obesity in primary care practice: an overview with perspective from the POWER-UP study , 2013, International Journal of Obesity.
[9] A. Wong,et al. Efficacy and safety of lorcaserin in obese adults: a meta‐analysis of 1‐year randomized controlled trials (RCTs) and narrative review on short‐term RCTs , 2013, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[10] G. Bray,et al. Pharmacologic Treatment Options for Obesity: What Is Old Is New Again , 2013, Current Hypertension Reports.
[11] J. McGill,et al. AACE comprehensive diabetes management algorithm 2013. , 2013, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[12] S. Oparil,et al. Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2). , 2013, The American journal of cardiology.
[13] S. Kahan,et al. Obesity Drug Outcome Measures: Results of a Multi-Stakeholder Critical Dialogue , 2013, Current Obesity Reports.
[14] Dennis D. Kim,et al. A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II) , 2013, Obesity.
[15] T. Wadden,et al. Annals of the New York Academy of Sciences Managing Obesity in Primary Care Practice: a Narrative Review , 2022 .
[16] G. Bray,et al. Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. , 2012, Archives of internal medicine.
[17] S. Hernández-Díaz,et al. Use of topiramate in pregnancy and risk of oral clefts. , 2012, American journal of obstetrics and gynecology.
[18] E. Colman,et al. The FDA's assessment of two drugs for chronic weight management. , 2012, The New England journal of medicine.
[19] V. Moyer,et al. Screening for and Management of Obesity in Adults: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.
[20] M. Lauer. Lemons for Obesity , 2012, Annals of Internal Medicine.
[21] P. O'Neil,et al. Randomized Placebo‐Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM‐DM Study , 2012, Obesity.
[22] Jin-fang Xu,et al. Effect of Anti-Obesity Drug on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2012, PloS one.
[23] M. Perri,et al. The impact of extended care on the long‐term maintenance of weight loss: a systematic review and meta‐analysis , 2012, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[24] N. Marchionni,et al. Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis , 2012, Experimental diabetes research.
[25] W. Baine,et al. The Agency for Healthcare Research and Quality , 2006, Italian Journal of Public Health.
[26] E. Colman. Food and Drug Administration's Obesity Drug Guidance Document: A Short History , 2012, Circulation.
[27] A. D'Angelo,et al. Effects of 1‐year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes , 2012, Journal of clinical pharmacy and therapeutics.
[28] G. Bray,et al. Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study , 2012, Diabetes Care.
[29] K. Gadde,et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study , 2011, The American journal of clinical nutrition.
[30] K. Gadde,et al. Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP) , 2011, Obesity.
[31] A. Astrup,et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide , 2011, International Journal of Obesity.
[32] A. Powell. Two-year sustained weight loss and metabolic benefits with controlled-release Phentermine/Topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study , 2012 .
[33] Katherine M Flegal,et al. Prevalence of obesity in the United States, 2009-2010. , 2012, NCHS data brief.
[34] F. Greenway,et al. Blood Pressure and Heart Rate Effects, Weight Loss and Maintenance During Long‐Term Phentermine Pharmacotherapy for Obesity , 2011, Obesity.
[35] N. Weissman,et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. , 2011, The Journal of clinical endocrinology and metabolism.
[36] D. Drucker,et al. The safety of incretin-based therapies--review of the scientific evidence. , 2011, The Journal of clinical endocrinology and metabolism.
[37] T. Wadden,et al. Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes , 2011, Diabetes Care.
[38] K. Gadde,et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.
[39] D. Singh-Franco,et al. The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta‐analysis , 2011, Diabetes, obesity & metabolism.
[40] C. Rock,et al. Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR‐BMOD Trial , 2011, Obesity.
[41] S. Rössner,et al. Long‐term changes in blood pressure following orlistat and sibutramine treatment: a meta‐analysis , 2010, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[42] A. Serretti,et al. Antidepressants and body weight: a comprehensive review and meta-analysis. , 2010, The Journal of clinical psychiatry.
[43] L. Aronne,et al. Enhanced Weight Loss Following Coadministration of Pramlintide With Sibutramine or Phentermine in a Multicenter Trial , 2010, Obesity.
[44] F. Greenway,et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial , 2010, The Lancet.
[45] N. Weissman,et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. , 2010, The New England journal of medicine.
[46] C. Correll,et al. Effectiveness of Medications Used to Attenuate Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-Analysis , 2010, Neuropsychopharmacology.
[47] J. Rosenstock,et al. Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes , 2010, Diabetes Care.
[48] F. Greenway,et al. How Physician Obesity Specialists Use Drugs to Treat Obesity , 2009, Obesity.
[49] T. Wadden,et al. One‐year Weight Losses in the Look AHEAD Study: Factors Associated With Success , 2009, Obesity.
[50] K. Gadde,et al. Combination pharmaceutical therapies for obesity. , 2009, Expert opinion on pharmacotherapy.
[51] Long term pharmacotherapy for obesity and overweight: updated meta-analysis , 2007, BMJ : British Medical Journal.
[52] D. Lau,et al. overweight: updated meta-analysis Long term pharmacotherapy for obesity and , 2007 .
[53] William Caplan,et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. , 2007, Journal of the American Dietetic Association.
[54] M. Etminan,et al. Long-term persistence with orlistat and sibutramine in a population-based cohort , 2007, International Journal of Obesity.
[55] L. V. Van Gaal,et al. The safety of obesity drugs – correspondence , 2007, Expert opinion on drug safety.
[56] D. Ryan,et al. Prediction of response to sibutramine therapy in obese non‐diabetic and diabetic patients , 2006, Diabetes, obesity & metabolism.
[57] J. Cutler,et al. Obesity research--limitations of methods, measurements, and medications. , 2006, JAMA.
[58] T. Wadden,et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. , 2005, The New England journal of medicine.
[59] F. Greenway,et al. Safety of obesity drugs , 2005, Expert opinion on drug safety.
[60] B. Swinburn,et al. Effect of orlistat on cardiovascular disease risk in obese adults , 2005, Diabetes, obesity & metabolism.
[61] C. Berne. A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin , 2005, Diabetic medicine : a journal of the British Diabetic Association.
[62] P. Shekelle,et al. Meta-Analysis: Pharmacologic Treatment of Obesity , 2005, Annals of Internal Medicine.
[63] L. K. Khan,et al. Prescription weight loss pill use among Americans: patterns of pill use and lessons learned from the fen-phen market withdrawal. , 2004, Preventive medicine.
[64] B. Hutton,et al. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. , 2004, The American journal of clinical nutrition.
[65] V. Schusdziarra,et al. Cholesterol lowering effect of dietary weight loss and orlistat treatment – efficacy and limitations , 2004, Alimentary pharmacology & therapeutics.
[66] L. Sjöström,et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. , 2004, Diabetes care.
[67] D. Lau,et al. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials , 2003, International Journal of Obesity.
[68] M. Krempf,et al. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity , 2003, International Journal of Obesity.
[69] K. Gadde,et al. Zonisamide for weight loss in obese adults: a randomized controlled trial. , 2003, JAMA.
[70] A. Rissanen,et al. Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines , 2003, International Journal of Obesity.
[71] M. Hanefeld,et al. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo‐controlled trial , 2002, Diabetes, obesity & metabolism.
[72] L. Aronne,et al. Erratum: Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin (Diabetes Care (2002) 25 (1123-1128)) , 2002 .
[73] J. Wilding,et al. RANDOMISED TRIAL OF THE EFFECT OF ORLISTAT ON BODY WEIGHT AND CARDIOVASCULAR DISEASE RISK PROFILE IN OBESE PATIENTS: UK MULTIMORBIDITY STUDY , 2002, International journal of clinical practice.
[74] L. Aronne,et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. , 2002, Diabetes care.
[75] W. Weiss. Pharmacotherapy for obesity. , 2002, The New England journal of medicine.
[76] S. Fowler,et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .
[77] W. Poston,et al. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials , 2002, International Journal of Obesity.
[78] G. Medeiros-Neto,et al. Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid) , 2001, International Journal of Obesity.
[79] F. Lindgärde. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study , 2000, Journal of internal medicine.
[80] G. Williams,et al. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor , 2000, International Journal of Obesity.
[81] C. Lucas,et al. Orlistat in the long-term treatment of obesity in primary care settings. , 2000, Archives of family medicine.
[82] S. Rössner,et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. , 2000, Obesity research.
[83] K. Fujioka,et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. , 1999, The American journal of clinical nutrition.
[84] S. Heymsfield,et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. , 1999, JAMA.
[85] Roy A Kaplan,et al. Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study , 1998, Diabetes Care.
[86] Alain Golay,et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients , 1998, The Lancet.
[87] B. Corya,et al. Valvular heart disease associated with fenfluramine-phentermine. , 1997, The New England journal of medicine.
[88] G G Enas,et al. Fluoxetine: a randomized clinical trial in the treatment of obesity. , 1994, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.
[89] E. C. Stein,et al. Long‐term weight control study II (weeks 34 to 104) , 1992, Clinical pharmacology and therapeutics.
[90] T. Silverstone. Intermittent treatment with anorectic drugs. , 1974, The Practitioner.
[91] A. J. Hadler. Sustained-action phendimetrazine in obesity. , 1968, The Journal of clinical pharmacology and the journal of new drugs.
[92] L. J. Duncan,et al. Comparison of continuous and intermittent anorectic therapy in obesity. , 1968, British medical journal.
[93] J. Runyan. Observations on the use of phendimetrazine, a new anorexigenic agent, in obese diabetics. , 1962, Current therapeutic research, clinical and experimental.